Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1992;86:531-537

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Buchwald, A. B.
Right arrow Articles by Wiegand, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Buchwald, A. B.
Right arrow Articles by Wiegand, V.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Cholesterol
Hazardous Substances DB
*TANTALUM

Circulation, Vol 86, 531-537, Copyright © 1992 by American Heart Association


ARTICLES

Low-molecular-weight heparin reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs

AB Buchwald, C Unterberg, K Nebendahl, HJ Grone and V Wiegand
Department of Cardiology, University of Gottingen, FRG.

BACKGROUND. Intracoronary stents have been suggested as a method of reducing the restenosis rate after balloon angioplasty. Proliferation of vascular smooth muscle cells is a major contributing factor to the restenosis process. Heparin and some of its derivatives have been shown to inhibit smooth muscle cell proliferation. We investigated the effect of low-molecular-weight heparin on the proliferative response after implantation of a balloon-expandable tantalum stent in previously deendothelialized coronary artery segments of hypercholesterolemic minipigs. METHODS AND RESULTS. Minipigs were fed a diet containing 2% cholesterol, starting 1 month before balloon denudation of the endothelium in a coronary artery. One month later, a stent was implanted at this site. Animals were killed after 4 weeks (group 1, n = 6) or 3 months (group 2, n = 6). Animals in group 3 (n = 6), also followed for 4 weeks after stenting, received subcutaneous low- molecular-weight heparin at a dose of 200-300 units/kg anti-factor Xa activity per day in addition to the chronic acetylsalicylic acid (100 mg/day) also administered to groups 1 and 2. Eighteen of 22 animals survived to the end of the study. Angiography revealed patent stents in all surviving animals. In group 1, histological analysis showed extensive neointimal proliferation around stent struts. Maximal neointimal thickness seen in group 1 averaged 0.93 +/- 0.11 mm, was lower after 3 months (0.8 +/- 0.14 mm) in group 2, but was significantly reduced (0.44 +/- 0.18 mm, p less than 0.01) in group 3. CONCLUSIONS. These data show a significant reduction of the neointimal proliferative response to coronary stent implantation by low-molecular- weight heparin.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. B. Buchwald, A. H. Wagner, C. Webel, and M. Hecker
Decoy oligodeoxynucleotide againstactivator protein-1 reducesneointimal proliferation after coronaryangioplasty in hypercholesterolemic minipigs
J. Am. Coll. Cardiol., February 20, 2002; 39(4): 732 - 738.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
J. Schweizer, A. Muller, L. Forkmann, G. Hellner, and W. Kirch
Potential Use of a Low-Molecular-Weight Heparin to Prevent Restenosis in Patients with Extensive Wall Damage Following Peripheral Angioplasty
Angiology, October 1, 2001; 52(10): 659 - 669.
[Abstract] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Arterioscler Thromb Vasc Biol, July 1, 2001; 21 (7): e9 - e9.
[Full Text] [PDF]


Home page
CirculationHome page
J. Hirsh, S. S. Anand, J. L. Halperin, and V. Fuster
Guide to Anticoagulant Therapy: Heparin : A Statement for Healthcare Professionals From the American Heart Association
Circulation, June 19, 2001; 103(24): 2994 - 3018.
[Full Text] [PDF]


Home page
ChestHome page
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Chest, January 1, 2001; 119 (2009): 64S - 94S.
[Full Text] [PDF]


Home page
Circ. Res.Home page
H. M. Nugent, C. Rogers, and E. R. Edelman
Endothelial Implants Inhibit Intimal Hyperplasia After Porcine Angioplasty
Circ. Res., March 5, 1999; 84(4): 384 - 391.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Y. Ueda, M. Kitakaze, M. Imakita, H. Ishibashi-Ueda, T. Minamino, H. Asanuma, T. Ozaki, E. Imamura, T. Kuzuya, and M. Hori
Glycoprotein IIb/IIIa Antagonist FK633 Could Not Prevent Neointimal Thickening in Stent Implantation Model of Canine Coronary Artery
Arterioscler Thromb Vasc Biol, February 1, 1999; 19(2): 343 - 347.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
L. Capron, J. Jarnet, D. Heudes, D. Joseph-Monrose, and P. Bruneval
Repeated Balloon Injury of Rat Aorta : A Model of Neointima With Attenuated Inhibition by Heparin
Arterioscler Thromb Vasc Biol, September 1, 1997; 17(9): 1649 - 1656.
[Abstract] [Full Text]


Home page
CirculationHome page
P. A. Hardhammar, H. M.M. van Beusekom, H. U. Emanuelsson, S. H. Hofma, P. A. Albertsson, P. D. Verdouw, E. Boersma, P. W. Serruys, and W. J. van der Giessen
Reduction in Thrombotic Events With Heparin-Coated Palmaz-Schatz Stents in Normal Porcine Coronary Arteries
Circulation, February 1, 1996; 93(3): 423 - 430.
[Abstract] [Full Text]


Home page
CirculationHome page
R. L. Geary, N. Koyama, T. W. Wang, S. Vergel, and A. W. Clowes
Failure of Heparin to Inhibit Intimal Hyperplasia in Injured Baboon Arteries : The Role of Heparin-Sensitive and -Insensitive Pathways in the Stimulation of Smooth Muscle Cell Migration and Proliferation
Circulation, June 15, 1995; 91(12): 2972 - 2981.
[Abstract] [Full Text]